Key Takeaways
- TRIUMPH-2 was a phase 3, double-blind, parallel-group, randomised, placebo-controlled trial of retatrutide in adults with obesity and type 2 diabetes, published in The Lancet in October 2026.
- Retatrutide is a single-molecule agonist acting at GIP, GLP-1, and glucagon receptors — a triple-agonist design studied for obesity, type 2 diabetes, and other comorbidities.
- The trial ran at 92 medical and research centres and hospitals across eight countries and randomly assigned 1,152 participants to retatrutide 4 mg, 9 mg, 12 mg, or placebo.
- Its population and goals differ from the knee osteoarthritis TRIUMPH research reported separately; different populations cannot be merged into one conclusion.
- Retatrutide remains investigational and unapproved: JAMA reported in October 2026 that it is being sold through online gray-market channels, which carry documented risks for buyers.
TRIUMPH-2 is the phase 3 randomised trial testing retatrutide in adults with obesity and type 2 diabetes, published in The Lancet on October 10, 2026. This explainer covers how the trial was designed, who was studied, what the published record reports, and what the evidence does — and does not — establish, in research-education framing.
Research boundary: This article is scientific education, not medical advice. WebberScience materials are for research and laboratory use only, not for human or veterinary use. No dosing, route, administration, treatment, personal-use, efficacy-promise, or self-experimentation guidance is provided anywhere on this site.
What Retatrutide Is: A Triple-Receptor Agonist
One molecule, three receptor targets
Retatrutide is described in the trial report as an agonist of the GIP, GLP-1, and glucagon receptors. That design is often summarized as “triple agonist”: one engineered peptide engaging three signaling targets that each participate in metabolic regulation.
A triple agonist label describes receptor-target design, not proven clinical superiority. The trial report separates what the molecule is designed to do from what the randomized data actually showed, and this article keeps that distinction throughout.
- GIP receptor
- A receptor involved in glucose- and lipid-related endocrine signaling; one of three targets engaged by retatrutide’s design.
- GLP-1 receptor
- A receptor tied to glucose-dependent endocrine signaling, appetite-related pathways, and gastrointestinal physiology; engagement is shared across the GLP-1-agonist research class.
- Glucagon receptor
- A receptor with important roles in hepatic and energy-balance biology; the third target in retatrutide’s design.
Because retatrutide is the same compound carried in WebberScience’s GLP-3 (Ret) research catalog, understanding the trial record matters for evaluating any third-party claim about it. See the site’s GLP-3 (Ret) research brief for catalog-side context.
What TRIUMPH-2 Tested
Design: a phase 3 placebo-controlled randomised trial
According to the peer-reviewed report, TRIUMPH-2 was a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Participants were randomly assigned 1:1:1:1 through an interactive web-response system to once-weekly subcutaneous study injections of placebo or retatrutide 4 mg, 9 mg, or 12 mg — labeled study amounts for the trial arms, not recommendations. The primary endpoint was percentage change from baseline to week 80 in bodyweight for the 9 mg and 12 mg groups versus placebo, with the 4 mg comparison as a key secondary endpoint. The trial is registered with ClinicalTrials.gov as NCT05929079 (completed).
Population and scale
The trial ran at 92 medical and research centres and hospitals across eight countries. Eligible adults had a BMI of 27 kg/m2 or higher and type 2 diabetes (glycated haemoglobin 6.5–10.5%) on stable treatment for at least 90 days before screening — diet or exercise alone, or up to three oral glucose-lowering medications — plus at least one self-reported unsuccessful dietary weight-reduction effort.
Between July 11, 2023, and November 1, 2024, 2,047 participants were screened and 1,152 were randomly assigned: 292 to the 4 mg group, 284 to 9 mg, 287 to 12 mg, and 289 to placebo. At baseline, mean BMI was 38.2 kg/m2, mean glycated haemoglobin was 7.71%, and 92% of participants were taking at least one oral glucose-lowering medication. Of 1,152 participants, 965 (84%) completed the study drug.
How the Results Should Be Read
What the published record reports
The abstract reports, under the treatment regimen estimand, the following model-based group means for bodyweight change at week 80:
| Study group | Mean bodyweight change at week 80 | Difference versus placebo (95% CI) |
|---|---|---|
| Placebo | −5.1% | — |
| Retatrutide 4 mg group (n=292) | −11.9% | −6.9 (−8.7 to −5.1) |
| Retatrutide 9 mg group (n=284) | −16.8% | −11.8 (−13.7 to −9.8) |
| Retatrutide 12 mg group (n=287) | −18.8% | −13.8 (−15.8 to −11.8) |
Values are transcribed from the published Lancet abstract for the treatment regimen estimand; group averages describe trial data and are not predictions for any individual, nor amounts to replicate.
The report’s interpretation states that treatment resulted in substantial improvements in bodyweight and was associated with improvements in glycaemic control in this population, with the authors noting the results indicate retatrutide might be effective for treating obesity in people with type 2 diabetes.
Evidence limits: estimands, funding, and the erratum culture
Three qualifications belong next to any headline number. First, these are model-based group estimates computed under a prespecified estimand with multiple imputation — not simple averages and not individual outcomes. Second, 84% of participants completed the study drug, so attrition shaped the analysis plan. Third, the trial was funded by Eli Lilly and Company, and the published conflict-of-interest statement identifies six authors as current Lilly employees and shareholders along with extensive consultant relationships among academic authors — industry funding does not invalidate a trial, but it is part of evidence appraisal.
Peer review itself evolves: correction and erratum records are a normal part of the contemporary trial literature (a recent same-pipeline example is the recorded erratum accompanying another 2026 phase 3 report). Reading the correction status of any anchor record before quoting it is now a standard QA step for evidence summaries.
How TRIUMPH-2 Differs from the Knee Osteoarthritis Research
Retatrutide is being investigated across multiple program workstreams. The table below separates the population studied in TRIUMPH-2 from other WebberScience-covered research on the same molecule so readers do not merge distinct trial intents.
| Research record | Population studied | Stage | What it examined | Where WebberScience covers it |
|---|---|---|---|---|
| TRIUMPH-2 (this article) | Adults with obesity and type 2 diabetes | Phase 3 randomised trial | Efficacy and safety versus placebo at 80 weeks | This article |
| Knee-OA TRIUMPH work | Knee osteoarthritis population | Reported 2026 trial research | Joint-related outcomes with the same molecule | GLP-3 (Ret) joint research: TRIUMPH 2026 |
| GLP-3 (Ret) safety signals | Cross-cutting class evidence | Standing research brief | Safety-signal literacy for the class and compound | GLP-3 (Ret) safety research brief |
Different populations, endpoints, and statistical plans cannot be averaged together. A result in adults with obesity and type 2 diabetes does not transfer automatically to a joint-symptom population or to any other group, which is why the site maintains separate explainers per research question.
Where Retatrutide Stands in 2026: Investigational Status and Gray-Market Risk
TRIUMPH-2 is a trial publication, not a regulatory authorization. Retatrutide is not FDA-approved, and JAMA’s October 2026 Medical News item names retatrutide among unapproved GLP-1 drugs sold online, describing the demand dynamics behind the online gray market and the potential risks for buyers of unapproved products. Trial momentum can create consumer demand that outpaces the regulatory process — the reverse of how authorization normally works.
WebberScience has covered the policy side of this gap separately in its expanded-access and compassionate-use explainer, which reviews how formal research-access pathways differ from informal online sales. The gray-market pattern is exactly the environment in which documentation quality — batch records, certificates of analysis, and honest labeling — separates research suppliers from resellers of unknown origin.
What This Trial Does Not Establish
- It does not make retatrutide an approved drug in the United States, Canada, or elsewhere; the trial record and approval status are separate things.
- It does not establish superiority versus semaglutide, tirzepatide, or any other specific drug, because no head-to-head randomized comparison was part of the reviewed sources.
- It does not transfer results to populations outside the trial’s eligibility criteria, including people without obesity or without type 2 diabetes.
- It does not resolve long-term durability, uncommon adverse events, or real-world effectiveness beyond the trial’s 80-week window and follow-up design.
- It does not convert group-level model estimates into individual predictions, and the labeled study amounts describe trial arms, not protocols to replicate.
- It does not support self-experimentation of any kind. WebberScience materials are for laboratory research only.
Key Terms and Definitions
- Triple agonist
- A single molecule designed to activate three receptor targets — here GIP, GLP-1, and glucagon.
- Phase 3 trial
- A late-stage randomized study designed to assess efficacy and safety in the target population at multicentre scale.
- Double-blind, parallel-group, placebo-controlled
- Neither participants nor investigators know assignments; separate groups run concurrently against an inactive comparator.
- Treatment regimen estimand
- The analysis question that follows outcomes for the assigned treatment regimen regardless of treatment discontinuation, with missing data handled by the prespecified imputation strategy.
- Investigational drug
- A molecule under study in trials that has not received regulatory marketing authorization.
Frequently Asked Questions About the Retatrutide TRIUMPH-2 Trial
What is retatrutide?
Retatrutide is a single-molecule agonist of the GIP, GLP-1, and glucagon receptors, designed as an investigational research drug and currently under study for obesity and related conditions.
What did TRIUMPH-2 study?
TRIUMPH-2 was a phase 3, double-blind, parallel-group, randomised, placebo-controlled trial testing the efficacy and safety of retatrutide versus placebo in adults with obesity and type 2 diabetes, at 92 centres across eight countries.
Who participated in TRIUMPH-2?
The trial randomly assigned 1,152 adults (mean age about 55 years) with a BMI of 27 kg/m2 or higher and type 2 diabetes on stable treatment, across retatrutide 4 mg, 9 mg, 12 mg, and placebo study groups.
What did the trial report at 80 weeks?
The published abstract reports mean bodyweight changes of -11.9%, -16.8%, -18.8%, and -5.1% for the 4 mg, 9 mg, 12 mg, and placebo groups respectively, under the treatment regimen estimand with multiple imputation. Percentages come from group averages and describe trial data, not individual outcomes.
How is TRIUMPH-2 different from the knee osteoarthritis research?
TRIUMPH-2 studied adults with obesity and type 2 diabetes. The separately reported knee osteoarthritis work studied a joint-symptom population. Different populations, endpoints, and trial aims cannot be pooled into one conclusion; WebberScience covers the knee-OA TRIUMPH work in its own article.
Is retatrutide approved by FDA or Health Canada?
No. JAMA reported in October 2026 that retatrutide is among unapproved GLP-1 drugs sold online. The TRIUMPH-2 report is a trial publication, not a regulatory authorization.
Why is retatrutide sold online if it is not approved?
JAMA Medical News attributes the online gray market to demand around trial results and describes potential risks of unapproved products. An investigational label does not authorize consumer use, and buyer due diligence is part of the publication’s message.
How does retatrutide differ from semaglutide or tirzepatide?
Receptor design differs: retatrutide engages GIP, GLP-1, and glucagon receptors. Head-to-head randomized comparisons against specific marketed drugs were not part of the sources reviewed here, so cross-trial rankings are not scientifically supportable.
What safety findings did TRIUMPH-2 report?
The most frequent adverse events were gastrointestinal, including diarrhoea and nausea, which were more common in retatrutide groups than placebo. Hypotension and dysesthesia were also reported more often with retatrutide. Discontinuation due to adverse events or death was most frequent in the 9 mg group at 12%, versus 5% for placebo. All deaths were deemed unrelated to the study intervention by the investigator.
Does WebberScience sell retatrutide?
WebberScience lists GLP-3 (Ret) 10mg and 5mg research materials. The labeled vial strength is product quantity only, not a dose, study amount, protocol, route, or evidence of equivalence to trial formulations. Products are for laboratory research use only.
Where is the primary evidence for this article?
The Lancet TRIUMPH-2 trial report (PMID 42810372, DOI 10.1016/S0140-6736(26)01861-1) and the JAMA Medical News piece on unapproved GLP-1 drugs sold online (PMID 42853576, DOI 10.1001/jama.2026.20514), both linked inline.
Primary and Authoritative Sources
- Bellido V, le Roux CW, Ekinci EI, et al. “Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.” The Lancet. 2026 Oct 10;408(10563):1455–1472. DOI 10.1016/S0140-6736(26)01861-1. PMID 42810372.
- ClinicalTrials.gov record NCT05929079 — the TRIUMPH-2 registration (completed).
- Rubin R. “Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.” JAMA Medical News. 2026 Oct 9. DOI 10.1001/jama.2026.20514. PMID 42853576.
- US FDA — “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Regulatory context for unapproved GLP-1 products.
Continue Retatrutide Research at WebberScience
For the 2026 trial-results context behind WebberScience’s GLP-3 (Ret) catalog, see the GLP-3 (Ret) trial results guide and the Peptide 101 primer. Qualified researchers can review the GLP-3 (Ret) 10mg research listing or the GLP-3 (Ret) 5mg research listing, both documented research materials. The labeled vial strength is product quantity only — not a dose, study amount, protocol, route, or evidence of equivalence to trial formulations.
Additional research-education context is available in the WebberScience Research Guides and the metabolic research guide.
Research disclaimer: For research and laboratory use only. Not intended for human or veterinary use. This article does not constitute medical advice, diagnosis, or treatment guidance. WebberScience provides no dosing, route, administration, treatment, efficacy, safety, or self-experimentation guidance.